Ocrelizumab: a review in multiple sclerosis
YN Lamb - Drugs, 2022 - Springer
Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: Clinician and patient perspectives [Narrative Review]
SD Newsome, C Binns, UW Kaunzner, S Morgan… - Neurology and …, 2023 - Springer
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption
BA Singer, J Feng, H Chiong-Rivero - Journal of Neurology, 2024 - Springer
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
[HTML][HTML] Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States
Y Song, Y Wang, SL Wong, D Yang, M Sundar… - Multiple Sclerosis and …, 2023 - Elsevier
Background Real-world evidence on the use of cladribine tablets (CladT) for relapsing forms
of multiple sclerosis (RMS) in the United States is emerging. The objective of this study was …
of multiple sclerosis (RMS) in the United States is emerging. The objective of this study was …
Treatment patterns by race and ethnicity in newly diagnosed persons with multiple sclerosis
CK Geiger, D Sheinson, TM To, D Jones… - Drugs-Real World …, 2023 - Springer
Abstract Background Non-Hispanic Black and Hispanic persons with MS (pwMS) are more
likely to experience rapid disease progression and severe disability than non-Hispanic …
likely to experience rapid disease progression and severe disability than non-Hispanic …
Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: a retrospective claims analysis
G Pardo, ED Pineda, CD Ng, KK Bawa… - Neurology and …, 2022 - Springer
Introduction We sought to assess adherence to and persistence with ocrelizumab (OCR)
compared with other disease-modifying treatments (DMTs), by route of administration (RoA) …
compared with other disease-modifying treatments (DMTs), by route of administration (RoA) …
Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world …
L Araujo, SS Geertsen, A Amedume, K Higuchi… - Neurology and …, 2022 - Springer
Introduction Therapeutic efficacy of disease-modifying therapies (DMTs) for multiple
sclerosis (MS) is often hindered by poor persistence and adherence, impacted by patient …
sclerosis (MS) is often hindered by poor persistence and adherence, impacted by patient …
[HTML][HTML] Adherence and discontinuation rates in patients on Tecfidera™(dimethyl fumarate): long-term Canadian experience from the Biogen ONE™ support program
MT Thompson, D Virginia, B Nick, G Melissa… - Multiple Sclerosis and …, 2022 - Elsevier
Background Tecfidera™(dimethyl fumarate [DMF]; Biogen) is an oral disease-modifying
therapy (DMT) indicated in Canada for the treatment of relapsing-remitting multiple sclerosis …
therapy (DMT) indicated in Canada for the treatment of relapsing-remitting multiple sclerosis …
Demographic patterns of MS patients using BRISA: an MS-specific app in Germany
P Balakrishnan, J Groenberg… - Journal of Personalized …, 2022 - mdpi.com
Background: Multiple sclerosis (MS) is a chronic, progressive neurological autoimmune
disease impacting quality of life. BRISA is an app designed to help MS patients in Germany …
disease impacting quality of life. BRISA is an app designed to help MS patients in Germany …
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
M Moccia, G Affinito, G Berera, G Marrazzo… - Journal of …, 2022 - Springer
Aims We aim to provide real-world evidence on the use of ocrelizumab for treating multiple
sclerosis (MS), with specific regard to prescription pattern, adherence, persistence …
sclerosis (MS), with specific regard to prescription pattern, adherence, persistence …